Astellas adds to global development team

Promotes Mark Weinberg to VP Global Clinical Science and appoints Robin McGarry as Head of Global Medical Safety

Astellas Pharma Global Development, a subsidiary of Astellas Pharma based in Tokyo, Japan, has promoted Mark Weinberg to Vice President of Global Clinical Science and has appointed Robin McGarry as Vice President, Global Medical Safety Head.

Weinberg joined Astellas in 2011 as Global Therapeutic Area Head in CNS and Pain. He has more than 14 years of experience in the pharmaceutical industry, working across multiple therapeutic areas. Prior to Astellas he was at Lundbeck where he focused on CNS.

McGarry has more than 25 years of experience in the pharmaceutical industry, including positions in clinical development and medical affairs at four different companies, and was Vice President of Worldwide Safety at Pfizer. For the past 13 years, she has been an independent consultant, providing pharmacovigilance, clinical, and regulatory strategic consulting services.